The purpose of this study is to determine the proportion of children presenting to a
pediatric emergency department with an acute mental health/behavioral crisis or clinical drug
toxicity who have a "match" or "mismatch" between the genes for drug metabolizing enzymes and
their current or recent drug therapy. The investigators will utilize a readily available and
FDA-approved cheek swab DNA test --GeneSight®--in these children that categorizes patients
into 3 different type of groups - RED, YELLOW, and GREEN based on individuals' abilities to
metabolize psychotropic drugs . Specific objectives include:
- The relationship of genomic mismatch to serum drug concentrations, either low or high
- The proportion of children with a genomic mismatch who present to PED with intentional
- The relationship between match versus mismatch and self- and caregiver-reported outcomes
of functioning, drug efficacy, and drug tolerability.
- Examine the proportion of children/adolescents who present to PED with an adverse drug
reaction to one or more psychotropic with a genomic mismatch.
- Quantify the specific adverse reactions related to a mismatch of genotypes.